VEGFA and age-related macular degeneration: In vivo, 17V05 was more potent in the inhibition of laser-induced CNV than aflibercept, a marketed VEGF inhibitor currently used as the standard of care for AMD, and exhibited stronger and longer inhibitory effects in a persistent retinal neovascularization (RNV) model [31] than conbercept, another marketed VEGF inhibitor.